- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT06458907
TRICAV-II Pivotal: sistema di valvole TRIcvalve biCAVal per grave rigurgito tricuspidale. (TRICAV-II)
Uno studio clinico prospettico, multicentrico, randomizzato sul sistema di valvole bicavali transcatetere TricValve in soggetti con grave rigurgito tricuspidale (TR).
Pivotal trial to evaluate the safety and effectiveness of the P&F TricValve® Transcatheter Bicaval Valve System.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
The study is a prospective, multi-center, randomized controlled pivotal clinical trial to evaluate the safety and effectiveness of the TricValve System with optimal medical therapy (OMT) compared to OMT alone in the treatment of patients with severe tricuspid regurgitation and unsuitable for approved transcatheter therapies. Subjects will be followed at discharge, 1 month, 30 days, 3 months, 6 months 12 months, and annually up to 5 years.
Tipo di studio
Iscrizione (Stimato)
Fase
- Non applicabile
Contatti e Sedi
Contatto studio
- Nome: Thuy Olender
- Numero di telefono: +1 408-839-3809
- Email: tolender@productsandfeatures.com
Luoghi di studio
-
-
Alabama
-
Birmingham, Alabama, Stati Uniti, 35233
- University of Alabama
-
-
Arizona
-
Phoenix, Arizona, Stati Uniti, 85013
- St. Joseph's Hospital and Medical Center
-
-
California
-
Sacramento, California, Stati Uniti, 95817
- UC Davis Health
-
San Diego, California, Stati Uniti, 92037
- Scripps Memorial Hospital La Jolla
-
San Francisco, California, Stati Uniti, 94143
- UCSF
-
San Jose, California, Stati Uniti, 94118
- Kaiser Permanente
-
Investigatore principale:
- Andrew Rassi, MD
-
Contatto:
- Cristina Casias
- Numero di telefono: 510-318-4224
- Email: cristina.casias@kp.org
-
-
District of Columbia
-
Washington D.C., District of Columbia, Stati Uniti, 20010
- MedStar Washington Hospital Center (MWHC)
-
Contatto:
- Erin Collins
-
Investigatore principale:
- Toby Rogers, MD
-
-
Florida
-
Delray Beach, Florida, Stati Uniti, 33484
- Delray Medical Center
-
Largo, Florida, Stati Uniti, 33770
- HCA Florida Largo Hospital
-
Investigatore principale:
- Saurabh Sanon, MD
-
Contatto:
- Holly-Lynn Grospitch
- Numero di telefono: 727-631-3721
- Email: hollylynn-grospitch@hcahealthcare.com
-
Tampa, Florida, Stati Uniti, 33606
- Tampa General Hospital
-
-
Illinois
-
Glenview, Illinois, Stati Uniti, 60026
- Endeavor Health
-
-
Indiana
-
Indianapolis, Indiana, Stati Uniti, 46260
- Ascension Medical Group St. Vincent The Heart Center of Indiana
-
-
Kansas
-
Kansas City, Kansas, Stati Uniti, 66103
- University of Kansas Medical Center
-
-
Louisiana
-
Houma, Louisiana, Stati Uniti, 70360
- Cardiovascular Institute of the South
-
Investigatore principale:
- Peter Fail, MD
-
Contatto:
- Jenny Aucoin
- Numero di telefono: 985-873-5037
- Email: jennifer.aucoin@cardio.com
-
-
Massachusetts
-
Boston, Massachusetts, Stati Uniti, 02215
- Beth Israel Deaconess Medical Center
-
Boston, Massachusetts, Stati Uniti, 02114
- Massachusetts General Hospital
-
Burlington, Massachusetts, Stati Uniti, 01805
- Lahey Hospital & Medical Center
-
-
Minnesota
-
Minneapolis, Minnesota, Stati Uniti, 55407
- Minneapolis Heart Institute Foundation
-
-
Missouri
-
Kansas City, Missouri, Stati Uniti, 64111
- Saint Luke's Mid America Heart Institute
-
St Louis, Missouri, Stati Uniti, 63110
- Washington University of St Louis
-
-
New Jersey
-
Hackensack, New Jersey, Stati Uniti, 07601
- Hackensack University Medical Center
-
-
New York
-
Manhasset, New York, Stati Uniti, 11030
- Northwell Hospital
-
The Bronx, New York, Stati Uniti, 10467
- Montefiore Medical Center
-
-
Ohio
-
Cleveland, Ohio, Stati Uniti, 44106
- Cleveland Clinic
-
Investigatore principale:
- Rishi Puri, MD
-
Columbus, Ohio, Stati Uniti, 43214
- Riverside Methodist Hospital
-
-
Oregon
-
Portland, Oregon, Stati Uniti, 97239
- Oregon Health
-
Investigatore principale:
- Firas Zahr, MD
-
Contatto:
- Halie Ropp
- Numero di telefono: 503-494-1147
- Email: ropph@ohsu.edu
-
-
South Carolina
-
Charleston, South Carolina, Stati Uniti, 29425
- MUSC
-
-
Texas
-
Houston, Texas, Stati Uniti, 77030
- Houston Methodist
-
Houston, Texas, Stati Uniti, 77030
- University of Texas (Memorial Hermann)
-
Plano, Texas, Stati Uniti, 75093
- Baylor Scott & White Medical
-
-
Utah
-
Murray, Utah, Stati Uniti, 84107
- Intermountain Heart Institute - Intermountain Medical Center
-
Investigatore principale:
- Brian Whisenant, MD
-
Contatto:
- McKenna Jensen
- Numero di telefono: 801-917-0978
- Email: mcKenna.jensen@imail.org
-
-
Virginia
-
Charlottesville, Virginia, Stati Uniti, 22903
- UVA School of Medicine
-
Norfolk, Virginia, Stati Uniti, 23507
- Sentara Healthcare
-
Roanoke, Virginia, Stati Uniti, 24014
- Carilion Clinic
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Eligibility Criteria for Randomized Cohort:
Inclusion Criteria:
- Age between 18 years and 85 years old, at the time of signing the informed consent.
- Severe tricuspid regurgitation (TR) and Caval Reflux (CR), as determined by the qualifying transthoracic echocardiogram (TTE) confirmed by an echocardiography Core Lab. TVARC criteria will be used for the definition of TR severity.
- NYHA Class II-III-IVa (not on inotropes, IABP or LVAD) or heart failure (HF) admission in the past 6 months.
- Adequately treated with optimal medical therapy (OMT) for heart failure per the local Heart Team at the time of TR assessment for eligibility (TTE). OMT includes stable oral diuretic medications.
- High risk for open surgery and is appropriate for transcatheter tricuspid therapies according to the local heart team.
- Patient is unsuitable for approved transcatheter therapies and is eligible for the TricValve procedure, based on review of screening/baseline data and imaging core lab measurements by Central Screening Committee.
- For females of childbearing potential, negative pregnancy test.
- Capable and willing to provide signed informed consent
Exclusion Criteria:
CONCOMITANT PROCEDURES
-
Patient had a recent MI, stroke, or cardiovascular accident; underwent coronary artery bypass graft surgery, had a percutaneous coronary intervention or other major cardiovascular surgery within 90 days prior to TricValve implantation.
-
Patient requires another planned major cardiac procedure, including left-sided transcatheter intervention or surgery (e.g. severe aortic stenosis, severe mitral regurgitation), coronary artery bypass or PCI or pulmonary valve correction.
CARDIOVASCULAR CONDITIONS
-
LVEF ≤ 30% on echocardiography.
-
Evidence of intracardiac, inferior vena cava (IVC), or femoral venous mass, thrombus or vegetation.
-
Severe right ventricular dysfunction.
-
Cardiac amyloidosis.
-
Pulmonary artery systolic pressure (PASP) >65 mmHg assessed with Echo Doppler and /or right heart catheterization.
-
Lower extremity venous thrombosis and/or the presence of an IVC filter at the time of or 6 months prior to the TricValve procedure.
-
Hemodynamically significant pericardial effusion.
-
Hemodynamic instability, cardiogenic shock, inotropic support, intra-aortic balloon pump or acute heart failure within 30 days prior to the TricValve procedure.
-
Patient with refractory heart failure requiring advanced intervention (i.e. left ventricular assist device, transplantation) (ACC/ AHA/ ESC/ EACTS Stage D heart failure).
-
Presence of significant congenital or acquired heart disease such as RV dysplasia, arrhythmogenic RV or other conditions that could interfere with the TricValve procedure.
ALLERGIES / INTOLERANCE
-
Any known allergy or hypersensitivity to nitinol, bovine tissue, or contrast media that cannot be adequately treated with pre-medication.
-
Unable to tolerate anticoagulation/antiplatelet therapy
COMORBIDITIES
-
Any known life-threatening condition with an estimated life span of less than 12 months.
-
Platelet count < 75,000/mm3
-
Child-Pugh Severity Class C (10-15 points).
-
Severe renal insufficiency with estimated glomerular filtration rate (eGFR) ≤ 30 mL/min/1.73 m2 or requiring chronic renal replacement therapy at the time of enrollment.
-
Endocarditis or active/ongoing infection requiring antibiotics.
-
Unable to walk at least 100 meters in a 6-minute walk test.
-
Known bleeding or clotting disorders or patient refuses blood transfusion.
-
Active gastrointestinal (GI) bleeding within 3 months of TricValve procedure.
-
Prior Malignancy: this study excludes participants at material risk of near-term cancer-related morbidity/mortality that could confound 12-month outcomes. This study allows the inclusion of fully treated, remote malignancies with documented No Evidence of Disease (NED)" criteria
a. History of any malignancy within 5 years prior to randomization or any active malignancy, except: i. Adequately treated non-melanoma skin cancer (basal or squamous cell) with no evidence of disease, or ii. Carcinoma in situ (e.g., cervical, breast DCIS) treated with curative intent and no evidence of disease.
b. Participants with a prior malignancy diagnosed >5 years before randomization are eligible if they meet all of the "No Evidence of Disease (NED)" criteria as specified below: i. No signs/symptoms of cancer on history and physical exam per standard of care; ii. No radiologic evidence of disease on surveillance imaging if such imaging is routinely indicated for that tumor type (not protocol-mandated); iii. Tumor markers (if applicable for that cancer) not suggestive of recurrence (e.g., stable/undetectable within site's lab reference and oncologist's judgment); iv. No active anti-cancer therapy (cytotoxic chemotherapy, immunotherapy, targeted therapy, radiotherapy) and none planned; v. Treating oncologist's attestation (or primary physician if oncology follow-up is complete) that the participant is disease-free and appropriate for participation.
GENERAL EXCLUSIONS
-
Use or participation in other investigational device or drug study in which the patient has not reached a primary endpoint to treat cardiovascular conditions related to the outcomes of the current study.
-
Any other condition that would preclude the ability to meet study requirements in the opinion of the investigator.
-
Psychiatric/behavioral issues or other medical or social conditions that preclude valid consent and follow-up
-
Pregnant or breastfeeding subjects and those who plan pregnancy during the clinical investigation follow-up period.
Eligibility Criteria for Single Arm Cohort:
Inclusion Criteria:
- Age > 85 years.
- NYHA Class III-IV, on intravenous inotropes, IABP or LVAD.
- LVEF ≤ 30% on echocardiography.
- Severe RV dysfunction.
- Severe pulmonary hypertension (PH), defined as Pulmonary artery systolic pressure (PASP) >65 mmHg assessed with Echo Doppler and /or mean Pulmonary Artery Pressure (mPAP >35) by right heart catheterization.
- Renal insufficiency: eGFR between 25 and 30 mL/min/ 1.73 m² or on chronic renal replacement therapy.
- Patient unable to walk a minimum distance of 100 mt during 6 minute walk test.
- Prior malignancy not meeting the requirements applied for the Randomized Cohort, specified in Exclusion Criterion #23.
- Comorbidities precluding inclusion in the Randomized Cohort (exclusion criteria #15 to #24).
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: TricValve System + Optimal medical therapy (OMT)
Heterotopic Transcatheter Valve Replacement (TVR) with the TricValve System in conjunction with optimal medical therapy (OMT) in patients with caval reflux and tricuspid regurgitation. |
• Heterotopic Transcatheter Valve Replacement (TVR) with the TricValve System in conjunction with optimal medical therapy
Altri nomi:
Optimal medical therapy
Altri nomi:
|
|
Comparatore attivo: Optimal medical therapy (OMT) Alone
OMT alone in patients with caval reflux and tricuspid regurgitation |
Optimal medical therapy
Altri nomi:
|
|
Sperimentale: TricValve Single Arm Registry
Single-Arm Registry for Heterotopic Transcatheter Valve Replacement (TVR) with the TricValve System in conjunction with OMT in patients with caval reflux and tricuspid regurgitation who are not eligible for randomization |
• Heterotopic Transcatheter Valve Replacement (TVR) with the TricValve System in conjunction with optimal medical therapy
Altri nomi:
Optimal medical therapy
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Randomized Cohort: Caval Reflux (CR) grade reduction
Lasso di tempo: 6 months
|
Reduction in Caval Reflux (CR) assessed by the echocardiography core laboratory. The CR will be assessed using the 3-grade scale: Grade 1 (no reflux, reflux extending for less than 1 cm below the diaphragm), Grade 2 ( reflux extending for less than 3 cm), Grade 3 (reflux of 3 cm or more). Lower grades of CR are better. |
6 months
|
|
Randomized Cohort: Hierarchical composite endpoint including: Kansas City Cardiomyopathy Questionnaire (KCCQ) improvement, New York Heart Association (NYHA) functional class improvement, and 6-minute walk test distance improvement
Lasso di tempo: 6 months
|
Comparison of clinical outcomes using a single hierarchical analysis. Treatment effect will be summarized using Win Ratio statistics, where a value greater than 1 indicates improved outcomes in the experimental group compared with the comparator arm. |
6 months
|
|
Randomized Cohort: Rate of Major Adverse Events (MAE)
Lasso di tempo: 30 days
|
Rate of Major Adverse Events (MAE) in experimental arm (TricValve + OMT) |
30 days
|
|
Randomized Cohort: Hierarchical composite endpoint: all-cause mortality, RVAD implantation or heart transplant, tricuspid valve surgery or percutaneous tricuspid intervention, heart failure hospitalizations, KCCQ improvement, NYHA functional class improv
Lasso di tempo: 1 year
|
Comparison of clinical outcomes using a single hierarchical analysis. Treatment effect will be summarized using Win Ratio statistics, where a value greater than 1 indicates improved outcomes in the experimental group compared with the comparator arm. |
1 year
|
|
Registry Cohort: Rate of Major Adverse Events (MAE)
Lasso di tempo: 30 days
|
Rate of Major Adverse Events (MAE) in single arm registry |
30 days
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Randomized Cohort: Percentage of Device- and/or Procedure-related MAEs
Lasso di tempo: 1 year
|
Rate of Major Adverse Events |
1 year
|
|
Randomized Cohort: All-Cause mortality and Cardiovascular Mortality
Lasso di tempo: 6 months and 1 year
|
Number of deaths from any cause as well as cardiovascular events |
6 months and 1 year
|
|
Randomized Cohort: Heart Failure Hospitalizations (HFH)
Lasso di tempo: 6 months and 1 year
|
Number of Heart Failure Hospitalizations and worsening HF events without hospitilization |
6 months and 1 year
|
|
Randomized Cohort: RVAD Implantation or Heart Transplant
Lasso di tempo: 6 months and 1 year
|
Number of patients requiring RVAD Implantation or Heart Transplant |
6 months and 1 year
|
|
Randomized Cohort: Atrial Fibrillation
Lasso di tempo: 1 year
|
New onset of atrial fibrillation |
1 year
|
|
Randomized Cohort: Quality of life as measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ) .
Lasso di tempo: 6 months and 1 year
|
Improvement of at least 10 points from baseline. KCCQ overall summary score is a patient-reported measure of health status, ranging from 0 to 100, where higher scores reflect better Quality of Life (QOL) |
6 months and 1 year
|
|
Randomized Cohort: Changes in symptom status New York Heart Association (NYHA class)
Lasso di tempo: 6 months and 1 year
|
Reduction of at least 1 class from baseline. The NYHA functional classification system categorizes heart failure patients into 4 classes based on physical activity limitation and symptom severity: class I (no symptoms and no limitation in ordinary physical activity), class II (mild symptoms and slight limitation during ordinary activity), class III (marked limitation in activity due to symptoms, even during less-than-ordinary activity; comfortable only at rest, and class IV (severe limitations; experiences symptoms even while at rest). |
6 months and 1 year
|
|
Randomized Cohort: Changes in functional capacity (6-minute walk test, 6MWT).
Lasso di tempo: 6 months and 1 year
|
Improvement of 6-minute walk distance of at least 30 meters from baseline. |
6 months and 1 year
|
|
Registry Cohort: Heart Failure Hospitalization
Lasso di tempo: 1 year
|
Comparison of the 12-month post-procedure HFH rate with the 12-month pre-procedure rate |
1 year
|
|
Registry Cohort: Changes in Quality of life (by Kansas City Cardiomyopathy Questionnaire (KCCQ) overall summary score).
Lasso di tempo: 1 year
|
Change from baseline to 12 months. KCCQ overall summary score is a patient-reported measure of health status, ranging from 0 to 100, where higher scores reflect better Quality of Life (QOL) |
1 year
|
|
Roll-In Cohort: Percentage of Device- and/or Procedure-related MAEs
Lasso di tempo: 1 year
|
Rate of Major Adverse Events |
1 year
|
|
Roll-In Cohort: All-Cause mortality and Cardiovascular Mortality
Lasso di tempo: 6 months and 1 year
|
Number of deaths from any cause as well as cardiovascular events |
6 months and 1 year
|
|
Roll-In Cohort: Heart Failure Hospitalizations (HFH)
Lasso di tempo: 6 months and 1 year
|
Number of Heart Failure Hospitalizations and worsening HF events without hospitalization |
6 months and 1 year
|
|
Roll-In Cohort: RVAD Implantation or Heart Transplant
Lasso di tempo: 6 months and 1 year
|
Number of patients requiring RVAD Implantation or Heart Transplant |
6 months and 1 year
|
|
Roll-In Cohort: Atrial Fibrillation
Lasso di tempo: 1 year
|
New onset of atrial fibrillation |
1 year
|
|
Roll-In Cohort: Quality of life as measured by Kansas City Cardiomyopathy Questionnaire (KCCQ).
Lasso di tempo: 6 months and 1 year
|
Improvement of at least 10 points from baseline. KCCQ overall summary score is a patient-reported measure of health status, ranging from 0 to 100, where higher scores reflect better Quality of Life |
6 months and 1 year
|
|
Roll-In Cohort: New York Heart Association (NYHA) functional class
Lasso di tempo: 6 months and 1 year
|
Reduction of at least 1 class from baseline. NYHA functional classification system categorizes heart failure patients into 4 classes based on physical activity limitation and symptom severity: class I (no symptoms and no limitation in ordinary physical activity), class II (mild symptoms and slight limitation during ordinary activity), class III (marked limitation in activity due to symptoms, even during less-than-ordinary activity; comfortable only at rest, and class IV (severe limitations; experiences symptoms even while at rest). |
6 months and 1 year
|
|
Roll-In Cohort: 6-minute walk test (6MWT).
Lasso di tempo: 6 months and 1 year
|
Improvement of 6-minute walk distance of at least 30 meters from baseline. |
6 months and 1 year
|
Collaboratori e investigatori
Sponsor
Collaboratori
Pubblicazioni e link utili
Pubblicazioni generali
- Amat-Santos IJ, Estevez-Loureiro R, Sanchez-Recalde A, Cruz-Gonzalez I, Pascual I, Mascherbauer J, Abdul-Jawad Altisent O, Nombela-Franco L, Pan M, Trillo R, Moreno R, Delle Karth G, Blasco-Turrion S, Sanchez-Luna JP, Revilla-Orodoea A, Redondo A, Zamorano JL, Puri R, Iniguez-Romo A, San Roman A. Right heart remodelling after bicaval TricValve implantation in patients with severe tricuspid regurgitation. EuroIntervention. 2023 Aug 7;19(5):e450-e452. doi: 10.4244/EIJ-D-23-00077. No abstract available.
- Blasco-Turrion S, Briedis K, Estevez-Loureiro R, Sanchez-Recalde A, Cruz-Gonzalez I, Pascual I, Mascherbauer J, Abdul-Jawad Altisent O, Nombela-Franco L, Pan M, Trillo R, Moreno R, Delle Karth G, Sanchez-Luna JP, Gonzalez-Gutierrez JC, Revilla-Orodoea A, Zamorano JL, Gomez-Salvador I, Puri R, San Roman JA, Amat-Santos IJ. Bicaval TricValve Implantation in Patients With Severe Symptomatic Tricuspid Regurgitation: 1-Year Follow-Up Outcomes. JACC Cardiovasc Interv. 2024 Jan 8;17(1):60-72. doi: 10.1016/j.jcin.2023.10.043. Epub 2023 Dec 6.
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- CTP-TRIC-005-II
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .